OXFORD HEALTH NHS FOUNDATION TRUST
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Private
- Established
- 2011-02-01
- Employees
- 5K
- Market Cap
- -
Clinical Trials
8
Active:1
Completed:5
Trial Phases
1 Phases
Not Applicable:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Not Applicable
6 (100.0%)Investigating the Clinical Utility of the Oxford Virtual Autism Assessment Tool (OVAAT)
Not Applicable
Recruiting
- Conditions
- Autism Spectrum DisorderHealthyNeurotypical
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-09-03
- Lead Sponsor
- Oxford Health NHS Foundation Trust
- Target Recruit Count
- 60
- Registration Number
- NCT06582290
- Locations
- 🇬🇧
Oxford Health NHS Foundation Trust, Oxford, United Kingdom
Self-compassion and Quality of Life After Dementia Diagnosis
Recruiting
- Conditions
- Dementia
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Oxford Health NHS Foundation Trust
- Target Recruit Count
- 23
- Registration Number
- NCT06465173
- Locations
- 🇬🇧
Oxford Health NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom
Enhanced Care Home Outcomes: A Qualitative Study
Completed
- Conditions
- Staff Attitude
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Oxford Health NHS Foundation Trust
- Target Recruit Count
- 19
- Registration Number
- NCT02703792
- Locations
- 🇬🇧
Department of psychological services, Fulbrook centre, Oxford, Oxfordshire, United Kingdom
Guided Self-help for Binge Eating
Not Applicable
Completed
- Conditions
- Bulimia NervosaEating Disorder Not Otherwise SpecifiedBinge Eating Disorder
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Oxford Health NHS Foundation Trust
- Target Recruit Count
- 122
- Registration Number
- NCT01832792
- Locations
- 🇬🇧
Oxford Health NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom
News
Epilepsy Drug Ezogabine Shows Promise as Novel Depression Treatment by Targeting Brain Potassium Channels
Two recent studies reveal that ezogabine, an FDA-approved epilepsy medication, may effectively treat depression by normalizing hyperactivity in the brain's reward circuitry through KCNQ potassium channel modulation.